Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
Date:5/30/2013

SAN FRANCISCO, May 30, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 2013 Jefferies Global Healthcare Conference in New York at the Grand Hyatt Hotel on Tuesday, June 4, 2013 at 9:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted in the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until July 8, 2013.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In a
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/19/2014)... Aug. 19, 2014   Lincor Inc. ... experience technology to New Jersey ... agreement, CarePoint Health will deploy Lincor,s PatientLINC technology ... Christ Hospital and Hoboken University Medical Center. ... of software solutions to help hospitals reach new ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder ... present a scientific poster describing an innovative diagnostic procedure ... 2014: Shedding New Light on Disease (SPEC) conference in ... Dr. Treado,s poster entitled, "Development of in vitro Diagnostics ... will be discussed during the conference poster session on ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... CINCINNATI, Ohio , June 29 Dr. Harry J. ... speaker and panel discussion participant at the 2010 Central Regional Meeting of ... June 16-19, 2010 .  The 2010 CeRMACS attracted over 400 participants and ... chemical disciplines.   , , ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems,Ltd. (Nasdaq: DHRM ), an emerging leader in the ... ,today announced members of its Executive Management will ring the NASDAQ Stock,Market closing bell ... , , ... , , ...
Cached Medicine Technology:Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell 2Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell 3
(Date:8/20/2014)... Caddis Partners LLC, has built one ... real estate company in recent years, developing or acquiring ... $500 million, including more than $100 million last year ... expansions into new geographic regions and a wider array ... pleased to announce an enhanced brand identity that includes ...
(Date:8/20/2014)... US (PRWEB) August 20, 2014 ... access, governmental and physician stakeholders networks impacting the ... Latin America, US, Canada, and Emerging Markets. , ... Heartbeat Experts’ perspectives on stakeholder management needs for ... new immunotherapy and targeted therapy investigational agents that ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 In its latest ... and alcohol treatment program that gets clients off to a ... they can believe in, is highlighting an important and possibly ... heeded by everyone who wants to understand the insidious nature ... of the belief that drug abuse targets a certain socioeconomic ...
(Date:8/20/2014)... August 20, 2014 The Academy of ... Lokhandwala, DDS, FAGD of Starbrite Dental in Fremont, California, ... 2014 Annual Meeting & Exhibits, which took place June ... presented to dentists who seek to provide the highest-quality ... earn this prestigious honor, Dr. Lokhandwala completed 500 hours ...
(Date:8/20/2014)... 20, 2014 (HealthDay News) -- White, straight women are ... minority, bisexual or lesbian women, a new study finds. ... women, aged 21 to 44, who took part in ... the National Survey of Family Growth study. In ... said they sought treatment for infertility. This ranged from ...
Breaking Medicine News(10 mins):Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Fremont Dentist Receives Prestigious AGD Fellowship Award 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2
... Ames, Iowa Byron Brehm-Stecher, assistant professor in food ... his work with tiny particles. His latest research project ... silver nanoparticles to improve the safety of the worlds ... directly to foods, the ultimate goal of this project ...
... April 10 Clinsys Clinical Research, a,therapeutically ... launch of Clinsys ALTERNA, which utilizes its ... resource services. The new,division demonstrates Clinsys, commitment ... and the life sciences industry,s continuously evolving,staffing ...
... parents have taken their children to a podiatrist,for foot ... and foot pain bring thousands of adults to doctors, ... by the American,Podiatric Medical Association (APMA) during April,s Foot ... of foot,health when it comes to their children,s feet. ...
... The National,Community Pharmacists Association (NCPA) is endorsing Rep. ... 3rd,Congressional District, who has been a powerful advocate ... patients. He is facing a,challenger in the North ... RPh, executive vice president and CEO of NCPA ...
... April 10 Health Environments Research &,Design Journal ... is to enhance the knowledge and practice of,evidence-based ... trends, and translating research to practice. The,vision of ... result of enhancing,healthcare environments for those receiving and ...
... independent ... auditors, LOUISVILLE, Colo., ... a result of its first Type,II SAS 70 compliance audit. The SAS ... U.S. accounting firm over a,period of five months. The audit covered GHX,s ...
Cached Medicine News:Health News:Iowa State University researcher looks to use nanoparticles for food safety 2Health News:Clinsys(R) Redefines Resource Services with the Launch of Clinsys ALTERNA(TM) 2Health News:Pediatric Survey Reveals Many Parents Neglect Their Children's Feet 2Health News:The Center for Health Design & Vendome Group Unveil Premiere Issue of Health Environments Research & Design Journal (HERD) - http://www.herdjournal.com 2Health News:GHX Achieves SAS 70 Compliance 2
Bi-phasic peristaltic infusion pump for tumescent work....
Inquire...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
... VASER System represents a major advance ... to cosmetic procedures. Combined with precision ... emulsification, a solid grooved probe design ... System has been designed to minimize ...
Medicine Products: